In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ESC statement concerning the systematic review and meta-analysis on digoxin published in the EHJ

Heart Failure (HF)
Atrial Fibrillation


On 5th May, the European Heart Journal (1) published a meta-analysis associating digitalis use with death in published patient cohorts of heart failure and/or atrial fibrillation. The analysis does not report any new findings, and the main conclusions are based on “observational data”.

The ESC guidelines on HF management (2) recommend either digoxin (or digoxin glycosides) to prevent hospitalizations due to HF decompensation and to improve breathlessness in HF patients who have poor heart function. They also recommend digitalis to slow ventricular rate in patients with atrial fibrillation. We believe that the current recommendations reflect the available evidence from clinical trials, prospectively designed to evaluate the effects of digoxin in HF patients. The analysis published by EHJ, as all meta-analyses, may be prone to some inherent drawbacks, which can have a strong impact on the validity of the final conclusion. In line with this consideration, the largest randomized trial of digitalis in heart failure patients, the DIG trial, did not find an increased mortality in patients randomized to digitalis.

The ESC will consider this new analysis of existing data, together with other recent reports on digitalis and cardiovascular outcomes, in the current re-write of the atrial fibrillation and heart failure guidelines. We do not see an immediate need to change the existing recommendations. Patients who are treated with digitalis and who want further advice on their treatment based on this analysis should see their physician for careful re-evaluation and further discussion.

 

ESC Press Office

press@escardio.org

+334 9294 8627